Around 9% of inflammatory bowel disease (IBD) patients are resistant to azathioprine. We hypothesized that these patients may carry mutations within inosine-5 0 -monophosphate dehydrogenase (IMPDH). To test this hypothesis, we screened 20 azathioprine-resistant patients for variations in the two IMPDH genes (IMPDH1 and IMPDH2) using dHPLC and DNA sequencing. A 9 bp insertion within the IMPDH1 P3 promoter was found in a patient exhibiting severe azathioprine resistance. The insertion is predicted to abolish a cAMP-response element (CRE) and was found to significantly reduce IMPDH1 P3 promoter activity in a luciferase reporter gene assay (P-value o0.001). This in vitro assay suggests the variant promoter has altered function in vivo and consequently may have contributed to the thiopurine resistance observed in this patient. The absence of functional variants within the other patients indicates that if IMPDH genetic variability contributes to azathioprine resistance it does so infrequently.
Introduction
Azathioprine is an immunosuppressant that undergoes complex metabolism resulting in the generation of several inactive products as well as the active metabolites 6-methylmercaptopurine ribonucleotides (6-MMPR), 6-thio-guanine nucleotides (6-TGN) and 6-thio-inosine triphosphate (6-thio-ITP) 1 ( Figure 1 ). The ratio between 6-MMPR and 6-TGN is a major determinant of the efficacy and toxicity of AZA. [2] [3] [4] A high ratio can result in treatment failure and toxic side effects. 3, [5] [6] [7] [8] [9] [10] Although azathioprine is widely used in the management of inflammatory bowel disease (IBD) approximately 9% of patients are resistant to thiopurine therapy. 4, 11 These patients are unable to achieve therapeutic concentrations of 6-TGN and accumulate 6-MMPR to hepatotoxic concentrations. Patients are considered to fit the definition of thiopurine resistance if the ratio between 6-MMPR and 6-TGN concentrations within red blood cells (RBCs) exceeds 30:1. 11 In most cases azathioprine resistance has been attributed to ultrahigh thiopurine S-methyltransferase (TPMT, EC 2.1.1.67) activity. However, only 1-2% of Caucasians exhibit ultra-high TPMT activity. 12 As the incidence of thiopurine resistance is far greater than the apparent incidence of ultra-high TPMT activity, we hypothesized that mutations within another purinemetabolizing enzyme, inosine-5 0 -monophosphate dehydrogenase (IMPDH, EC 1.1.1.205), may be an alternative cause of thiopurine resistance in our population. To test this hypothesis, we screened IBD patients who responded to azathioprine and patients who had normal TPMT activity but who were resistant to azathioprine for sequence variations in the two genes encoding IMPDH (IMPDH1 and IMPDH2).
13,14
Results IBD patients showing resistance to azathioprine had 6-MMPR:6-TGN ratios ranging from 32:1 to 212:1. TPMT enzyme activities of all IBD patients in this study were between 10.9 and 17.0 IU/ml, indicating none of the azathioprine-resistant patients or responders exhibited ultra-high TPMT activity. 9 Twenty azathioprine-resistant patients and 17 azathioprine-responders were screened for genetic variability in IMPDH using dHPLC. DNA sequencing confirmed the presence of 12 IMPDH1 variants, including two synonymous SNPs (L329L and A525A), one intronic SNP, and four P3 promoter variants, across the 37 IBD patients (Table 1 and Figure 2a ). The P3 promoter variants, including a 9 bp insertion, were found in a single azathioprine-resistant patient with a 6-MMPR:6-TGN ratio of 100:1 (Table 1) . All other IMPDH1 variants were either common to both groups or detected solely in azathioprine-responders. Our sample size provided 480% power to detect a statistically significant (two-tailed, a ¼ 0.05) difference in relative risks of between two-and 10-fold for variant rates across these groups (depending on baseline variant rates). Consequently, we are confident that no profound differences in variant rates between azathioprine groups were missed as a consequence of inadequate statistical power. In contrast, the only sequence variation detected in IMPDH2 was a SNP (4999C4T) located in intron 11 (Table 1 and Figure 2b ). Of the 13 sequence variants detected in our IBD patients only the IMPDH1 synonymous SNPs 11401G4C (rs2288550) and15328G4A (rs228075) were among the IMPDH SNPs lodged with NCBI dbSNP. To our knowledge, all other IMPDH variants found in this study have not been previously reported in this public database (Table 1) .
To assess whether any of the mutations located within the IMPDH1 P3 sequence altered promoter activity, the wildtype and variant sequences were cloned into a luciferase reporter vector. The resulting wild-type and variant promoter luciferase constructs exhibited expression levels of 8.1670.37 and 6.1970.01, respectively. The percentage of maximal expression of the variant promoter relative to the wild-type IMPDH promoter across three transfections was 75.9%, indicating that the variant caused a subtle but significant decrease in IMPDH1 P3 promoter activity in COS-7 cells (non-parametric Mann-Whitney U-test, P-value o0.001). A search of transcription factor binding sites, using TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html) and the CREB Target Gene database (http://natural.salk.edu/ CREB), found the 9 bp insertion disrupted a putative cAMP-response element (CRE) site within the IMPDH1 P3 promoter (Figure 3 ). In contrast, the three point mutations (À76T4C, À69A4G, and À66A4G) were not predicted to create or abolish a binding site for any known transcription factor ( Figure 3 ).
Two hundred controls and 100 azathioprine-responsive IBD patients, who were not included in the initial dHPLC analysis, were genotyped for the P3 promoter variants. None of the four sequence variants were found in either cohort, suggesting that this variability within the IMPDH1 P3 promoter is very rare or specific to this IBD patient (Table 1) .
Discussion
Approximately 9% of New Zealand IBD patients on azathioprine exhibit resistance to this drug. 9 It has been suggested that ultra-high TPMT enzyme activity is the primary cause of thiopurine resistance, 12 however, to our knowledge this has never been proven. In this study, all of the IBD patients resistant to azathioprine treatment had TPMT activities that were well within the normal range for our population, 9 consequently other factors must be Figure 1 Metabolism of thioprines. The pro-drug azathioprine (AZA) is quickly converted, via a non-enzymatic reaction, to 6-mercaptopurine (6-MP), which undergoes extensive metabolism via three competing pathways, mediated by xanthine oxidase (XO), thiopurine S-methyltransferase (TPMT), and hypoxanthine guanine phosphoribosyl transferase (HPRT), respectively. The pathway mediated by XO produces the inactive metabolite 6-thiouric acid (6-TU). TPMT catalyses the production of a second inactive metabolite (6-methymercaptopurine, 6-MMP). 1, 26, 27 The HPRT pathway generates 6-thioinosine monophosphate (6-TIMP). Once formed, 6-TIMP may be transformed into either thioguanine nucleotides (6-TGN) by the rate limiting inosine-5-monophosphate dehydrogenase (IMPDH) and guanine monophosphate synthetase (GMPS), methylated into 6-methylmercaptopurine ribonucleotides (6-MMPR) by TPMT or phosphorylated to 6-thio-inosine triphosphate (6-thio-ITP). 6-MMPR, 6-TGNs, and 6-thio-ITP are all active metabolites. In normal cells, the accumulation of 6-thio-ITP to toxic levels is prevented by inosine triphosphatase (ITPase), which converts 6-thio-ITP back to 6-TIMP. 28 AZA can act as an immunosuppressant through the random incorporation of 2 0 -deoxy-6-TGTP into DNA and RNA. [29] [30] [31] However, recent research has demonstrated that the primary way in which AZA exerts its immunosuppressive activity is by inhibiting the guanosine triphosphatase Rac1 in T lymphocytes. 32 responsible for causing thiopurine-resistance in this subset of patients. It is conceivable that genetic variability in IMPDH, another purine-metabolizing enzyme, may be an alternative cause of azathioprine resistance.
Human IMPDH activity is the result of two separate 56 kDa IMPDH enzymes, termed type I and type II, which have virtually identical catalytic activities and substrate affinities, and are 84% identical at the amino-acid level. In contrast, IMPDH2 is only 5.8 kb and although it has an identical ORF structure to IMPDH1, the introns and UTRs of this IMPDH gene are significantly smaller. 13 The relative location of variants identified by dHPLC analysis and DNA sequencing are shown with vertical arrows. Numbering of IMPDH1 and IMPDH2 variants is based on the genomic sequences from the UCSC Genome Browser (May 2004 Assembly). In both cases the nucleotide numbered þ 1 is the 'A' of the translational initiation codon (ATG) and the nucleotide 5 0 to þ 1 is numbered À1. Despite the similarities, differences in the regulation and expression of the two isoforms have been well-documented. In general, the level and pattern of IMPDH type I expression is more variable than that described for the type II isoform. 15 Much of this variability in IMPDH type I expression has been attributed to the existence of three promoters (P1, P2 and P3) within IMPDH1 that result in the generation of different mRNA transcripts. Of these, P3 is the major promoter producing a 2.5 kb transcript in most tissues. 13 Furthermore, knockout mouse models have demonstrated that IMPDH type I and type II, in addition to having different levels and patterns of expression, play distinct physiological roles. For example, a total deficiency in IMPDH type II during the early development of the mouse embryo cannot be compensated by IMPDH type I and results in death of the embryo. 16 In this study, we have identified novel mutations within the IMPDH1 P3 promoter that appeared exclusively in a patient exhibiting severe thiopurine resistance. To our knowledge, this is the first time that variability in IMPDH1 has been implicated in drug response. All previous mutations within this gene have been reported in patients with autosomal dominant retinitis pigmentosa or leber congenital amaurosis. 17, 18 The 9 bp insertion (À92-83insGAGCAG TAG) found in this azathioprine-resistant patient is predicted to disrupt a putative CRE site in the major IMPDH1 promoter. The cAMP-response element-binding protein (CREB) regulates gene expression by binding to a conserved CRE that occurs as either a palindrome (TGACGTCA) or a half site (CGTCA/TGACG). 19 A genome-wide analysis of CREB occupancy identified 4084 putative CREB target genes, including IMPDH1. 20 Although this insertion, and the point mutations À76T4C, À69A4G and À63A4G, collectively produced a relatively small decrease in IMPDH1 P3 promoter activity in vitro, it suggests the variant promoter has altered function which may be important in vivo. A study of the molecular mechanisms controlling IMPDH2 expression identified CRE sites as an important component of promoter activity in this gene. Mutagenesis of tandem CRE sites reduced IMPDH2 promoter activity by 83% in a transient CAT transfection assay. 21 Therefore, it is possible that the disruption of the sole CRE site within the P3 promoter was also sufficient to impair IMPDH1 expression and consequently caused or contributed to the thiopurine resistance observed in our IBD patient. However, the absence of functional variants in the promoter, UTRs and exons of IMPDH1 and IMPDH2 in the other azathioprine-resistant patients suggests that if IMPDH genetic variability contributes to thiopurine resistance it does so infrequently.
Materials and methods

Study participants
IBD patients who responded well to azathioprine and those that exhibited resistance to this thiopurine were recruited from gastroenterology clinics at the Christchurch Hospital (Christchurch, New Zealand). Controls living within the catchment area of Christchurch Hospital were recruited at random from the electoral roll. Details of the recruitment and the demographics of this control cohort have been described previously. 22 Informed consent was obtained from all study participants and ethical approval for this research was given by the Canterbury Ethics Committee of New Zealand. All study participants were unrelated and of Caucasian ethnicity.
IBD patients were defined as azathioprine-resistant if they had 6-MMPR:6-TGN ratios of 430:1 and no symptomatic improvement in IBD despite 44 months azathioprine therapy at 1.5-2.5 mg/kg/day. These patients had subtherapeutic 6-TGN concentrations (o235 pmol/8 Â 10 8 RBC) and 6-MMPR concentrations exceeding 45700 pmol/ 8 Â 10 8 RBC. They were predicted to have an increased likelihood of hepatotoxicity and treatment failure due to their 6-TGN and 6-MMPR concentrations. In contrast, individuals who experienced disease remission on 1.5-2.5 mg/kg/day were described as being responsive to azathioprine treatment. RBC concentrations of 6-TGN and 6-MMPR were determined using a previously described HPLC method. 9 To exclude elevated TPMT enzyme activity as the cause of azathioprine resistance, TPMT activity in RBCs was also determined for each study participant. Screening for variability in IMPDH1 and IMPDH2 DNA was collected from the peripheral blood of IBD patients and controls using guanidium isothiocyanate extraction 23 and rapid boiling lysis, 24 respectively. Twenty azathioprine-resistant and 17 azathioprineresponsive IBD patients were screened for mutations within IMPDH1 and IMPDH2 using dHPLC and confirmed by direct sequencing. The promoters, open reading frame, and untranslated regions (UTRs) of the IMPDH genes were amplified in 45 separate PCR fragments of 200 to 650 bp. Primers used to amplify the open reading frame of each gene were positioned approximately 50-100 bp from each intronexon boundary to maximize the detection of exonic SNPs and splice site variants. Primer sequences are available on request. PCR was carried out in a total volume of 25 ml, containing 200 mM dNTPs, 0.5 mM of each primer, 2.5 mM MgCl 2 , 1 U of Roche Taq Polymerase (Roche Diagnostics GmbH, Mannheim, Germany), Roche reaction buffer (2.5 ml), and B20 to 100 ng of genomic DNA. The thermal cycling conditions were as follows: 2 min at 941C (initial denaturation); 35 cycles of 30 s at 941C, 30 s at 581C, 40 s at 721C; and a final extension of 2 min at 721C.
Denaturing HPLC was performed on a WAVE DNA Fragment Analysis System (Transgenomics Inc., Omaha, NE, USA) equipped with a DNASep column. Unpurified PCR products were heated to 951C for 5 min and cooled slowly over 45 min to 251C to form heteroduplexes. Six microliters of each heteroduplexed PCR product was injected into the DNASep column and separated (flow rate of 0.9 ml/min) through a 2% linear acetonitrile gradient. The ratio of Buffer A to Buffer B, and oven temperatures for optimal SNP detection were pre-determined by WAVEMAKER Software Version 4.1.40. When more than one melting domain was predicted for an amplicon by the software, the dHPLC analysis was performed at two or more different temperatures. To reduce the probability of missing functionally relevant SNPs that occurred in a homozygous state, each amplicon derived from a case was heteroduplexed with an amplicon known from DNA sequencing to be identical to the IMPDH1 and IMPDH2 mRNA reference sequences (Genbank Accession numbers: NM_183243 and NM_000884). The resulting heteroduplexes and homo duplexes were analysed under the same conditions as the other samples. Amplicons that produced unusual dHPLC chromatograms were re-amplified, purified and sequenced in both directions on an ABI Prism 3100-Avant Genetic Analyzer (Applied Biosystems, CA, USA), using Big Dye Terminator chemistry (Applied Biosystems).
Generation of reporter constructs and transfection studies
The functional effect of sequence variants located in the P3 promoter of IMPDH1 was assessed using a luciferase reporter gene assay. Briefly, 842 bp of the variant and wild-type IMPDH1 P3 promoters were amplified and cloned into the firefly luciferase vector, pGL3-basic (Promega Corporation, Madison, WI, USA), using the BglI and HindIII sites. Constructs were confirmed by restriction endonuclease digestions and sequencing. Transfections into COS-7 cells (ATCC # CRL-1651) were performed in 24-well plates (5 Â 10 5 cells/well) using Effectene (Qiagen GmbH, Hilden, Germany) as per manufacturer's instructions. To control for variation in transfection efficiency among replicates, promoter constructs were co-transfected with the Renilla luciferase vector, pRL-TK, (Promega). At 36 h post-transfection, COS-7 cells were harvested and firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega). Luciferase activity was calculated as the ratio of firefly to Renilla Luciferase activity. Luciferase values were normalized with COS-7 cells that had been transfected solely with promoterless pGL3-basic vector. Each construct was tested in triplicate across three separate transfections.
IMPDH1 P3 promoter genotyping IBD patients not included in the initial dHPLC analysis and controls were genotyped for the IMPDH1 P3 promoter variants. The single base changes (À76T4C, À69A4G À63A4G) were detected using a dHPLC analysis temperature of 681C (44% buffer A, 56% buffer B), whereas a nondenaturing temperature of 501C was adopted to screen for the 9 bp insertion. 25 
